Not Signed In - Cytogen Announces Initiation Of Phase III Study Involving QUADRAMET(R)
Thu, 27 Jul 2006 06:00 AM EST
... Cytogen Corporation(Nasdaq: CYTO) today announced that the National Cancer Institute's (NCI)Radiation Treatment Oncology Group (RTOG) has initiated a randomized phaseIII trial to evaluate either QUADRAMET (samarium Sm-153 lexidronaminjection) or strontium-89 chloride in conjunction with zole [click link for full article] ...
Related Topics
- Antithrombin III
- Familial Dysautonomia
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Congenital antithrombin III deficiency
- Samarium 153 Lexidronam
- Cranial mononeuropathy III - compression type
- Cranial mononeuropathy III - diabetic type
- Antithrombin
- Radiation Studies
- Osteogenesis imperfecta, type III
- Inhalants
- PET Study
- Caregiving
- Clinical Trials
- Brain Diseases
- Peptic Ulcer
- Chondroitin
- VX
- Retinoblastoma
email this page
print this page
bookmark this page
feedback on this page
